Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Argenx announces positive CHMP Opinion for Vyvgart (efgartigimod alfa) subcutaneous injection for chronic inflammatory demyelinating polyneuropathy

Written by | 22 May 2025

Argenx SE announced the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended European Commission (EC) approval of Vyvgart  1000mg (efgartigimod alfa) for subcutaneous… read more.

Approval of efgartigimod alfa injection (subcutaneous injection) for generalized myasthenia gravis in China – Zai Lab + argenx

Written by | 22 Jul 2024

Zai Lab Limited and argenx announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC), 1,000mg… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.